Times Are Changing.

Nearly 40 million Americans are at risk for vision loss or blindness due to diabetes and age related macular degeneration. There is an unmet need for tools that empower doctors to better understand the early phases of these complex diseases, further monitor their progression and ultimately manage treatment. Often, these diseases are diagnosed and treated much too late, after irreversible vision loss has started to occur, leading to increased treatment costs for later disease stages and poorer patient outcomes – until now.

Learn More Learn More

500 million people globally are affected by major blinding eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy and glaucoma, and our new technology has the ability to identify it before it's too late.

Kieren Patel, Ph.D., J.D.CO-FOUNDER / CEO


Key Differences


Our Technology

OCT WITHOUT FUNCTIONAL IMAGING

  • Lacks predictive data
  • No oxygen saturation
  • No early detection
Before
After

OPTICENT OCT

  • High resolution structural and functional imaging
  • Detects retinal blood flow rate and sO2
  • Accurately captures changes in retinal metabolic activity
  • Uses functional OCT information to detect and monitor disease
img

Slide here toExperience the difference


SWITCHING IT UP


The Advantages

ocular

EARLY DISEASE
DETECTION

patience-comfort

IMPROVES PATIENT
COMFORT

healthcare

REDUCES HEALTHCARE
COSTS

treatment

OPTIMIZES TREATMENT
STRATEGY

Stay Updated

Recent News
& Resources